Cost-effectiveness of adjuvant interferon therapy after surgical resection of hepatitis C-related hepatocellular carcinoma

Yujin Hoshida, Yasushi Shiratori, Masao Omata

Research output: Contribution to journalArticle

9 Scopus citations

Abstract

Background: To evaluate cost-effectiveness of adjuvant interferon therapy used with surgical resection of hepatitis C-related primary hepatocellular carcinoma. Design: We constructed a Markov model that simulated adjuvant interferon therapy after resection of hepatitis C-related hepatocellular carcinoma, and evaluated life expectancy, costs, and cancer recurrence. The reference case is a 60-year-old man with hepatitis C-related compensated cirrhosis. Results: At the baseline, adjuvant interferon therapy yielded 6.1 life years with a cost of $77, 000, and an incremental cost-effectiveness ratios of $ 15, 700/life year compared with no interferon therapy. The proportion of patients who experienced recurrence of hepatocellular carcinoma until death was reduced from 87.6% to 62.9% using adjuvant interferon therapy. The incidence of recurrent hepatocellular carcinoma after interferon influenced the cost-effectiveness of adjuvant interferon therapy. A threshold analysis showed that adjuvant interferon therapy was not cost-effective (ICER = $ 27, 000/year) if the annual incidence of recurrent hepatocellular carcinoma after interferon is 16% (baseline 8.9%). The proportions of patients with recurrent hepatocellular carcinoma were 74.4% and 86.9% at the annual recurrence rates after interferon of 16% and 35%, respectively. Conclusions: Adjuvant interferon therapy after surgical resection of primary hepatitis C-related hepatocellular carcinoma improves life expectancy through suppression of recurrent cancer with acceptable cost-effectiveness.

Original languageEnglish (US)
Pages (from-to)479-485
Number of pages7
JournalLiver
Volume22
Issue number6
DOIs
StatePublished - Dec 2002

Keywords

  • Cost-effectiveness
  • Cost-effectiveness ratio-inferon
  • Hepatitis C
  • Hepatocellular carcinoma
  • Incremental
  • Interferon
  • Markov model
  • Surgical resection

ASJC Scopus subject areas

  • Hepatology

Fingerprint Dive into the research topics of 'Cost-effectiveness of adjuvant interferon therapy after surgical resection of hepatitis C-related hepatocellular carcinoma'. Together they form a unique fingerprint.

  • Cite this